Background - Growing evidence suggests that platelet reactivity (PR) may predict bleeding. We investigate the incremental value of PR in predicting bleeding after percutaneous coronary intervention (PCI) via the femoral approach over a validated bleeding risk score (BRS) of clinical and procedural variables. Methods and Results - A total of 800 patients undergoing elective PCI via the femoral approach were included. PR was measured before PCI with the VerifyNow P2Y12 assay and low PR was defined as a P2Y12 reaction unit value ≤178. Calculation of the BRS included the following: age, sex, intra-aortic balloon pump, glycoprotein IIb/IIIa inhibitors, chronic kidney disease, anemia, and low-molecular-weight heparin within 48-hour pre-PCI. A new risk score including low PR (BRS-PR) was developed and validated in an independent cohort of patients (n=310). Bleeding events at 30 days after PCI were defined according to the thrombolysis in myocardial infarction, Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2, and Bleeding Academic Research Consortium criteria. Both BRS and PR showed high discriminatory power for bleeding (area under the curve [AUC] >0.7 for all definitions). Discriminatory power of BRS-PR (AUC=0.809 for thrombolysis in myocardial infarction bleeding; AUC=0.814 for Bleeding Academic Research Consortium class ≥2 bleeding; AUC=0.708 for Bleeding Academic Research Consortium class ≥3 bleeding; and AUC=0.813 for REPLACE-2 bleeding) was significantly higher than that of BRS alone (P<0.001 for all bleeding definitions). In the validation set, BRS-PR showed higher discriminatory power for thrombolysis in myocardial infarction bleeding than BRS alone (AUC=0.788 versus 0.709; P=0.036). Conclusions - PR has incremental predictive value on bleeding events after elective PCI via the femoral approach over a validated risk score of clinical and procedural variables. A risk score including PR yields significantly better prognostic performance compared with the original BRS. © 2015 American Heart Association, Inc.

Incremental Value of Platelet Reactivity over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding after Percutaneous Coronary Intervention via the Femoral Approach: Development and Validation of a New Bleeding Risk Score / Mangiacapra, F; Ricottini, E; Barbato, Emanuele; Demartini, C; Peace, A; Patti, G; Vizzi, V; De Bruyne, B; Wijns, W; Di Sciascio, G.. - In: CIRCULATION. CARDIOVASCULAR INTERVENTIONS.. - ISSN 1941-7640. - 8:5(2015). [10.1161/CIRCINTERVENTIONS.114.002106]

Incremental Value of Platelet Reactivity over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding after Percutaneous Coronary Intervention via the Femoral Approach: Development and Validation of a New Bleeding Risk Score

BARBATO, EMANUELE;
2015

Abstract

Background - Growing evidence suggests that platelet reactivity (PR) may predict bleeding. We investigate the incremental value of PR in predicting bleeding after percutaneous coronary intervention (PCI) via the femoral approach over a validated bleeding risk score (BRS) of clinical and procedural variables. Methods and Results - A total of 800 patients undergoing elective PCI via the femoral approach were included. PR was measured before PCI with the VerifyNow P2Y12 assay and low PR was defined as a P2Y12 reaction unit value ≤178. Calculation of the BRS included the following: age, sex, intra-aortic balloon pump, glycoprotein IIb/IIIa inhibitors, chronic kidney disease, anemia, and low-molecular-weight heparin within 48-hour pre-PCI. A new risk score including low PR (BRS-PR) was developed and validated in an independent cohort of patients (n=310). Bleeding events at 30 days after PCI were defined according to the thrombolysis in myocardial infarction, Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2, and Bleeding Academic Research Consortium criteria. Both BRS and PR showed high discriminatory power for bleeding (area under the curve [AUC] >0.7 for all definitions). Discriminatory power of BRS-PR (AUC=0.809 for thrombolysis in myocardial infarction bleeding; AUC=0.814 for Bleeding Academic Research Consortium class ≥2 bleeding; AUC=0.708 for Bleeding Academic Research Consortium class ≥3 bleeding; and AUC=0.813 for REPLACE-2 bleeding) was significantly higher than that of BRS alone (P<0.001 for all bleeding definitions). In the validation set, BRS-PR showed higher discriminatory power for thrombolysis in myocardial infarction bleeding than BRS alone (AUC=0.788 versus 0.709; P=0.036). Conclusions - PR has incremental predictive value on bleeding events after elective PCI via the femoral approach over a validated risk score of clinical and procedural variables. A risk score including PR yields significantly better prognostic performance compared with the original BRS. © 2015 American Heart Association, Inc.
2015
fibrinogen receptor antagonist; low molecular weight heparin; aged; anemia; Article; bleeding; Bleeding Academic Research Consortium; bleeding risk score; blood clot lysis; chronic kidney disease; female; follow up; heart infarction; human; intraaortic balloon pump; major clinical study; male; percutaneous coronary intervention; platelet reactivity; priority journal; Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events 2; rating scale; scoring system; thrombocyte function analyzer; hemorrhage; percutaneous coronary intervention; platelet reactivity
01 Pubblicazione su rivista::01a Articolo in rivista
Incremental Value of Platelet Reactivity over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding after Percutaneous Coronary Intervention via the Femoral Approach: Development and Validation of a New Bleeding Risk Score / Mangiacapra, F; Ricottini, E; Barbato, Emanuele; Demartini, C; Peace, A; Patti, G; Vizzi, V; De Bruyne, B; Wijns, W; Di Sciascio, G.. - In: CIRCULATION. CARDIOVASCULAR INTERVENTIONS.. - ISSN 1941-7640. - 8:5(2015). [10.1161/CIRCINTERVENTIONS.114.002106]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1660314
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact